- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Health Informatics
- Immune System
- Kidneys and Urinary System
- Legal and Regulatory
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Palliative Care
- Pregnancy and Childbirth
- Public Health and Safety
- Sexual Health
- Skin, Hair and Nails
- Sports Medicine
- Substance Abuse
- Surgery and Rehabilitation
Measuring distress in people with Types 1 and 2 diabetes
Australian diabetes experts, psychiatrists and neuroscientists have reported the benefits of measuring depression and disease-related distress in patients with diabetes. They have also shown that distress is influenced by heritable genetic changes in the way patients’ bodies handle serotonin, a neurotransmitter that regulates mood.
Their aim is to help clinicians quickly identify those people who need psychiatric guidance or counseling to manage their diabetes and to provide practical ways of helping.
The most recent paper to come out of the study, now published online in Psychosomatics, relates control of blood sugar levels with the degree of disease-related distress (measured by a questionnaire known as PAID1).
A second paper, published online last year in Psychiatry Research and from the same study, examines the relationship between depression and anxiety and the presence or absence of a common variant in genes that regulate serotonin levels. The paper revealed that those with the risk variant had significantly higher disease-related distress.
The multidisciplinary collaborative effort included Professor Lesley Campbell, senior clinical researcher at the Garvan Institute of Medical Research and Director of Diabetes Services at St. Vincent’s Hospital; Professor Kay Wilhelm, a Liaison Psychiatrist and Research Director of Faces in the Street, the Urban Mental Health and Wellbeing Institute at St. Vincent’s Hospital; Psychiatry PhD student Dr Jaya Reddy; Professor Philip Mitchell, Professor of Psychiatry, University of NSW and Professor Peter Schofield, Executive Director of Neuroscience Research Australia.
One hundred and eighty four diabetes patients2 agreed to participate, 75% with Type 2 diabetes, 25% with Type 1 diabetes. Each person completed the PAID questionnaire, agreed to serotonin genotyping, and was interviewed to assess their depression history by either Professor Wilhelm or Dr Reddy.
“Our Psychosomatics paper clearly showed that diabetes-related distress predicts the level of chronic blood glucose control, and we saw a high level of distress in people related to their disease,” said Professor Campbell.
“When people are distressed, it interferes with their ability to look after themselves – and most clinicians are at sea as to how to handle that. They talk about non-compliant patients, but they don’t figure the distress of the patient as part of the story.”
“Although this study looks specifically at diabetes, it is also a paradigm for other chronic disease distress management, including coronary heart disease and stroke.”
In collaboration with Professor Schofield, Professor Wilhelm has been studying the effects of people’s serotonin genotype on their ability to regulate emotion. Those with a specific variant appear to be more excitable, less able to control their emotions in a crisis.
“Diabetes is known to be a chronic stressor – and we wanted to see if there were reliable ways of predicting stress, anxiety and depression to give doctors a practical way of helping people,” said Professor Wilhelm.
“It’s interesting to note that a person’s genetic make-up predicts their ability to cope with stress, and that in turn determines their level of distress.”
“While depression and distress both affect a person’s ability to cope with diabetes, distress is easier to measure with the PAID questionnaire and much more accurately predicts disease management.”
“We’re now working on an algorithm to identify people at risk and personalise their treatment options – using PAID as well as a measure of depression and anxiety. Ideally, we’d like to see patients complete a questionnaire in the waiting room. That would allow the treating clinician to see immediately whether or not they have a high distress score – and then give appropriate advice.”
“Importantly, we plan to give clinicians some ideas about what to do in the case of high distress. There are plenty of good evidence-based ways of dealing with stress. Some involve things like problem solving, some involve a technique called ‘mindfulness’ –a pre-meditation technique where you savour the moment and empty your mind. Mindfulness is extremely effective in giving people more emotional control – and in decreasing further episodes for people who have been depressed.”
“There are other things that help including bright light in the mornings, a good diet, staying away from tobacco and recreational drugs, and doing exercise.”
Professor Wilhelm has created a series of business card sized brief interventions to enable people to deal better with stressful situations, including chronic health conditions. She is making them into an app for smart phones.
Testing for genetic susceptibility to distress provides a useful mechanism for how individuals deal with stress and it may improve patient outcomes in the future, although further studies are needed to assess the benefits of this approach.
1. Disease-related distress is measured by PAID - the Problem Areas in Diabetes instrument - developed by the Joslin Diabetes Centre in Boston.
2. Patients attended diabetes clinics at St. Vincent’s and Prince of Wales Hospitals in Sydney.
The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent's Hospital in Sydney, it is now one of Australia's largest medical research institutions with over 600 scientists, students and support staff. Garvan's main research programs are: Cancer, Diabetes & Obesity, Immunology and Inflammation, Osteoporosis and Bone Biology and Neuroscience. Garvan's mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan's discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.
All media enquiries should be directed to:
Science Communications Manager
M: + 61 434 071 326
P: +61 2 9295 8128
E: a.heather "a" garvan.org.au